- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Personalized Care Key as Tirzepatide Use Expands Rapidly
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
On this episode of Managed Care Cast, we engage in a discussion with John M. Ostrominski, MD, fellow in cardiovascular medicine and obesity medicine, Brigham and Women’s Hospital and Harvard Medical School, and first author of a new study published in Annals of Internal Medicine, “Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States.”
First approved on May 13, 2022, to treat adult patients with type 2 diabetes, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist has since been approved for chronic weight management and obstructive sleep apnea. Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, Ostrominski and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes. Overall, their findings show a significant uptick in tirzepatide dispensations, alongside other glucose- and weight-lowering medications, including semaglutide.
Speaking to the impact of their findings on health care providers who treat patients for type 2 diabetes and/or obesity, Ostrominski explains that these findings “underscore the need and importance of personalized and shared decisions around treatment.”
Listen above or through one of these podcast services:
Nomogram Aids Early Detection of Myasthenic Crisis Risk
August 19th 2025Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.
Read More
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
